MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM.

NCT07608354 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2026-05-27

No results posted yet for this study

Summary

The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Interventions

DRUG

Eplontersen

Eplontersen delivered subcutaneously, once every 4 weeks

BIOLOGICAL

ALXN2220

ALXN2220 delivered intravenously, once every 4 weeks

OTHER

Placebo

Placebo delivered intravenously, once every 4 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-02-23
Completion
2029-02-23
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07608354 on ClinicalTrials.gov